

Dean D Metcalfe

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6119399/publications.pdf>

Version: 2024-02-01

169
papers

18,516
citations

11651
70
h-index

12272
133
g-index

170
all docs

170
docs citations

170
times ranked

11514
citing authors

#	ARTICLE	IF	CITATIONS
1	IgE, mast cells, basophils, and eosinophils. <i>Journal of Allergy and Clinical Immunology</i> , 2010, 125, S73-S80.	2.9	1,065
2	Diagnostic criteria and classification of mastocytosis: a consensus proposal. <i>Leukemia Research</i> , 2001, 25, 603-625.	0.8	1,020
3	Tryptase Levels as an Indicator of Mast-Cell Activation in Systemic Anaphylaxis and Mastocytosis. <i>New England Journal of Medicine</i> , 1987, 316, 1622-1626.	27.0	737
4	Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts. <i>Blood</i> , 2017, 129, 1420-1427.	1.4	520
5	Definitions, Criteria and Global Classification of Mast Cell Disorders with Special Reference to Mast Cell Activation Syndromes: A Consensus Proposal. <i>International Archives of Allergy and Immunology</i> , 2012, 157, 215-225.	2.1	513
6	Mast cells and mastocytosis. <i>Blood</i> , 2008, 112, 946-956.	1.4	481
7	Characterization of novel stem cell factor responsive human mast cell lines LAD 1 and 2 established from a patient with mast cell sarcoma/leukemia; activation following aggregation of Fc ϵ RI or Fc γ RI. <i>Leukemia Research</i> , 2003, 27, 677-682.	0.8	473
8	The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. <i>Blood</i> , 2002, 99, 1741-1744.	1.4	416
9	Cold Urticaria, Immunodeficiency, and Autoimmunity Related to PLCG2 Deletions. <i>New England Journal of Medicine</i> , 2012, 366, 330-338.	27.0	391
10	Anaphylaxis—a practice parameter update 2015. <i>Annals of Allergy, Asthma and Immunology</i> , 2015, 115, 341-384.	1.0	381
11	Assessment of the allergenic potential of foods derived from genetically engineered crop plants*. <i>Critical Reviews in Food Science and Nutrition</i> , 1996, 36, 165-186.	10.3	374
12	Demonstration That Human Mast Cells Arise From a Progenitor Cell Population That Is CD34+, c-kit+, and Expresses Aminopeptidase N (CD13). <i>Blood</i> , 1999, 94, 2333-2342.	1.4	359
13	Factors affecting the determination of threshold doses for allergenic foods: How much is too much?. <i>Journal of Allergy and Clinical Immunology</i> , 2002, 109, 24-30.	2.9	348
14	Mast cells in innate immunity. <i>Immunological Reviews</i> , 2000, 173, 131-140.	6.0	338
15	A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. <i>Blood</i> , 2004, 103, 3222-3225.	1.4	336
16	Activation of mast cells by double-stranded RNA: evidence for activation through Toll-like receptor 3. <i>Journal of Allergy and Clinical Immunology</i> , 2004, 114, 174-182.	2.9	314
17	Classification and Diagnosis of Mastocytosis: Current Status. <i>Journal of Investigative Dermatology</i> , 1991, 96, S2-S4.	0.7	307
18	Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 35-45.	2.9	289

#	ARTICLE	IF	CITATIONS
19	Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number. <i>Nature Genetics</i> , 2016, 48, 1564-1569.	21.4	279
20	Mast cell activation syndrome: Proposed diagnostic criteria. <i>Journal of Allergy and Clinical Immunology</i> , 2010, 126, 1099-1104.e4.	2.9	266
21	Mechanisms of mast cell signaling in anaphylaxis. <i>Journal of Allergy and Clinical Immunology</i> , 2009, 124, 639-646.	2.9	240
22	Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria. <i>Leukemia Research</i> , 2003, 27, 635-641.	0.8	217
23	Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. <i>Experimental Hematology</i> , 2003, 31, 686-692.	0.4	213
24	Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future. <i>Cancer Research</i> , 2017, 77, 1261-1270.	0.9	210
25	Human mast cells express functional TrkA and are a source of nerve growth factor. <i>European Journal of Immunology</i> , 1997, 27, 2295-2301.	2.9	209
26	Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with idiopathic anaphylaxis. <i>Blood</i> , 2007, 110, 2331-2333.	1.4	208
27	Diagnosis and treatment of systemic mastocytosis: state of the art. <i>British Journal of Haematology</i> , 2003, 122, 695-717.	2.5	187
28	Mastocytosis: Pathology, genetics, and current options for therapy. <i>Leukemia and Lymphoma</i> , 2005, 46, 35-48.	1.3	180
29	Expression of a Functional High-Affinity IgG Receptor, FcγRI, on Human Mast Cells: Up-Regulation by IFN-γ. <i>Journal of Immunology</i> , 2000, 164, 4332-4339.	0.8	176
30	Mast cells signal their importance in health and disease. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 381-393.	2.9	169
31	Human mast cells are capable of serotonin synthesis and release. <i>Journal of Allergy and Clinical Immunology</i> , 2007, 119, 498-499.	2.9	163
32	Impulse oscillometry in the evaluation of diseases of the airways in children. <i>Annals of Allergy, Asthma and Immunology</i> , 2011, 106, 191-199.	1.0	159
33	Understanding the mechanisms of anaphylaxis. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2008, 8, 310-315.	2.3	158
34	Vibratory Urticaria Associated with a Missense Variant in <i>ADGRE2</i> . <i>New England Journal of Medicine</i> , 2016, 374, 656-663.	27.0	157
35	Hematologic manifestations of systemic mast cell disease: A prospective study of laboratory and morphologic features and their relation to prognosis. <i>American Journal of Medicine</i> , 1991, 91, 612-624.	1.5	156
36	Proposed Diagnostic Algorithm for Patients with Suspected Mast Cell Activation Syndrome. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 1125-1133.e1.	3.8	150

#	ARTICLE	IF	CITATIONS
37	17-Allylamino-17-demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively activated KIT protein in human mast cells. <i>Blood</i> , 2004, 103, 1078-1084.	1.4	147
38	Kit and FcÎµRI mediate unique and convergent signals for release of inflammatory mediators from human mast cells. <i>Blood</i> , 2004, 104, 2410-2417.	1.4	144
39	Isolation and Characterization of Heparin from Human Lung. <i>Journal of Clinical Investigation</i> , 1979, 64, 1537-1543.	8.2	142
40	Gastrointestinal Dysfunction in Systemic Mastocytosis. <i>Gastroenterology</i> , 1988, 95, 657-667.	1.3	141
41	Heritable risk for severe anaphylaxis associated with increased Î±-tryptaseâ€œencoding germline copy number at TPSAB1. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 622-632.	2.9	137
42	Mast cell numbers in rheumatoid synovial tissues. <i>Arthritis and Rheumatism</i> , 1987, 30, 130-137.	6.7	133
43	Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal. <i>HemaSphere</i> , 2021, 5, e646.	2.7	128
44	International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis. <i>Blood</i> , 2013, 121, 2393-2401.	1.4	122
45	The biology of Kit in disease and the application of pharmacogenetics. <i>Journal of Allergy and Clinical Immunology</i> , 2004, 114, 13-19.	2.9	120
46	NTAL phosphorylation is a pivotal link between the signaling cascades leading to human mast cell degranulation following Kit activation and FcÂRI aggregation. <i>Blood</i> , 2004, 104, 207-214.	1.4	117
47	Frequency and characterization of antigen-specific IL-4â€œ and IL-13â€œ producing basophils and T cells in peripheral blood of healthy and asthmatic subjects. <i>Journal of Allergy and Clinical Immunology</i> , 1999, 104, 811-819.	2.9	112
48	Activation and Function of the mTORC1 Pathway in Mast Cells. <i>Journal of Immunology</i> , 2008, 180, 4586-4595.	0.8	112
49	Activation of human mast cells by aggregated IgG through FcÎ³RI: additive effects of C3a. <i>Clinical Immunology</i> , 2004, 110, 172-180.	3.2	109
50	Assessment of the extent of cutaneous involvement in children and adults with mastocytosis: Relationship to symptomatology, tryptase levels, and bone marrow pathology. <i>Journal of the American Academy of Dermatology</i> , 2003, 48, 508-516.	1.2	108
51	Mast cells as a unique hematopoietic lineage and cell system: From Paul Ehrlich's visions to precision medicine concepts. <i>Theranostics</i> , 2020, 10, 10743-10768.	10.0	107
52	Functional and phenotypic studies of two variants of a human mast cell line with a distinct set of mutations in the c-kit proto-oncogene. <i>Immunology</i> , 2003, 108, 89-97.	4.4	105
53	KIT D816Vâ€œassociated systemic mastocytosis with eosinophilia and FIP1L1/PDGFRÂ-associated chronic eosinophilic leukemia are distinct entities. <i>Journal of Allergy and Clinical Immunology</i> , 2007, 120, 680-687.	2.9	105
54	A Comparison of Mediators Released or Generated by IFN-Î³-Treated Human Mast Cells Following Aggregation of FcÎ³RI or FcÎµRI. <i>Journal of Immunology</i> , 2001, 166, 4705-4712.	0.8	101

#	ARTICLE	IF	CITATIONS
55	The Phospholipase C β 1-dependent Pathway of Fc ϵ RI-mediated Mast Cell Activation Is Regulated Independently of Phosphatidylinositol 3-Kinase. <i>Journal of Biological Chemistry</i> , 2003, 278, 48474-48484.	3.4	100
56	Rodent and Human Mast Cells Produce Functionally Significant Intracellular Reactive Oxygen Species but Not Nitric Oxide. <i>Journal of Biological Chemistry</i> , 2004, 279, 48751-48759.	3.4	95
57	Mast Cell Migratory Response to Interleukin-8 Is Mediated Through Interaction With Chemokine Receptor CXCR2/Interleukin-8RB. <i>Blood</i> , 1999, 93, 2791-2797.	1.4	93
58	Btk Plays a Crucial Role in the Amplification of Fc ϵ RI-mediated Mast Cell Activation by Kit. <i>Journal of Biological Chemistry</i> , 2005, 280, 40261-40270.	3.4	93
59	Silica-Directed Mast Cell Activation Is Enhanced by Scavenger Receptors. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2007, 36, 43-52.	2.9	92
60	Stem Cell Factor Programs the Mast Cell Activation Phenotype. <i>Journal of Immunology</i> , 2012, 188, 5428-5437.	0.8	90
61	Human tissue mast cells are an inducible reservoir of persistent HIV infection. <i>Blood</i> , 2007, 109, 5293-5300.	1.4	87
62	Why the 20% + 2 Tryptase Formula Is a Diagnostic Gold Standard for Severe Systemic Mast Cell Activation and Mast Cell Activation Syndrome. <i>International Archives of Allergy and Immunology</i> , 2019, 180, 44-51.	2.1	87
63	Clonal analysis of NRAS activating mutations in KIT-D816V systemic mastocytosis. <i>Haematologica</i> , 2011, 96, 459-463.	3.5	86
64	IL-6 promotes an increase in human mast cell numbers and reactivity through suppression of suppressor of cytokine signaling 3. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 1863-1871.e6.	2.9	86
65	Impact of naturally forming human β -tryptase heterotetramers in the pathogenesis of hereditary β -tryptasemia. <i>Journal of Experimental Medicine</i> , 2019, 216, 2348-2361.	8.5	85
66	Treatment of Three Patients with Systemic Mastocytosis with Interferon Alpha-2b. <i>Leukemia and Lymphoma</i> , 1996, 22, 501-508.	1.3	83
67	Functional Deregulation of KIT. <i>Immunology and Allergy Clinics of North America</i> , 2014, 34, 219-237.	1.9	81
68	Btk-dependent Rac activation and actin rearrangement following Fc ϵ RI aggregation promotes enhanced chemotactic responses of mast cells. <i>Journal of Cell Science</i> , 2010, 123, 2576-2585.	2.0	78
69	Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1348-1356.	2.0	76
70	Analysis of plasma histamine levels in patients with mast cell disorders. <i>American Journal of Medicine</i> , 1989, 87, 649-654.	1.5	73
71	Activated mast cells synthesize and release soluble ST2 α decoy receptor for IL β 3. <i>European Journal of Immunology</i> , 2015, 45, 3034-3044.	2.9	72
72	A distinct biomolecular profile identifies monoclonal mast cell disorders in patients with idiopathic anaphylaxis. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 180-188.e3.	2.9	70

#	ARTICLE	IF	CITATIONS
73	The ingenious mast cell: Contemporary insights into mast cell behavior and function. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 83-99.	5.7	69
74	The Phosphoinositide 3-Kinase-Dependent Activation of Btk Is Required for Optimal Eicosanoid Production and Generation of Reactive Oxygen Species in Antigen-Stimulated Mast Cells. <i>Journal of Immunology</i> , 2008, 181, 7706-7712.	0.8	66
75	Kit- and FcεRI-induced differential phosphorylation of the transmembrane adaptor molecule NTAL/LAB/LAT2 allows flexibility in its scaffolding function in mast cells. <i>Cellular Signalling</i> , 2008, 20, 195-205.	3.6	64
76	Comparison of FcμRI- and FcβRI-mediated degranulation and TNF-α synthesis in human mast cells: selective utilization of phosphatidylinositol-3-kinase for FcβRI-induced degranulation. <i>European Journal of Immunology</i> , 2003, 33, 1450-1459.	2.9	56
77	Diagnosis, Classification and Management of Mast Cell Activation Syndromes (MCAS) in the Era of Personalized Medicine. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9030.	4.1	56
78	Synergistic activation of phospholipases Cβ and Cγ: A novel mechanism for PI3K-independent enhancement of FcμRI-induced mast cell mediator release. <i>Cellular Signalling</i> , 2008, 20, 625-636.	3.6	55
79	Hematopathology of the Bone Marrow in Pediatric Cutaneous Mastocytosis: A Study of 17 Patients. <i>American Journal of Clinical Pathology</i> , 1989, 91, 558-562.	0.7	54
80	Immune mechanisms in food allergy. <i>Clinical and Experimental Allergy</i> , 1991, 21, 321-324.	2.9	54
81	Food allergens. <i>Clinical Reviews in Allergy</i> , 1985, 3, 331-349.	1.0	53
82	Assessing anaphylactic risk? Consider mast cell clonality. <i>Journal of Allergy and Clinical Immunology</i> , 2009, 123, 687-688.	2.9	53
83	Levels of mast-cell growth factors in plasma and in suction skin blister fluid in adults with mastocytosis: Correlation with dermal mast-cell numbers and mast-cell tryptase. <i>Journal of Allergy and Clinical Immunology</i> , 2002, 109, 82-88.	2.9	52
84	Association of the Q576R polymorphism in the interleukin-4 receptor α chain with indolent mastocytosis limited to the skin. <i>Blood</i> , 2001, 98, 880-882.	1.4	51
85	Determination of protein phosphorylation in FcμRI-activated human mast cells by immunoblot analysis requires protein extraction under denaturing conditions. <i>Journal of Immunological Methods</i> , 2002, 268, 239-243.	1.4	51
86	Mastocytosis. <i>Chemical Immunology and Allergy</i> , 2010, 95, 110-124.	1.7	50
87	Adverse reactions to drugs and biologics in patients with clonal mast cell disorders: A Work Group Report of the Mast Cells Disorder Committee, American Academy of Allergy, Asthma & Immunology. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 880-893.	2.9	50
88	Sialic acid-binding immunoglobulin-like lectin (Siglec) 8 in patients with eosinophilic disorders: Receptor expression and targeting using chimeric antibodies. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 2227-2237.e10.	2.9	50
89	Pathogenesis and Pathology of Mastocytosis. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2017, 12, 487-514.	22.4	49
90	mTORC1 and mTORC2 differentially regulate homeostasis of neoplastic and non-neoplastic human mast cells. <i>Blood</i> , 2011, 118, 6803-6813.	1.4	48

#	ARTICLE	IF	CITATIONS
91	CD72 Negatively Regulates KIT-Mediated Responses in Human Mast Cells. <i>Journal of Immunology</i> , 2010, 184, 2468-2475.	0.8	47
92	Effects of Gamma Radiation on Fc μ RI and TLR-Mediated Mast Cell Activation. <i>Journal of Immunology</i> , 2007, 179, 3276-3286.	0.8	46
93	Fc μ RI- and Fc γ 3 Receptor-Mediated Production of Reactive Oxygen Species by Mast Cells Is Lipoxygenase- and Cyclooxygenase-Dependent and NADPH Oxidase-Independent. <i>Journal of Immunology</i> , 2007, 179, 7059-7071.	0.8	45
94	The Role of c-Kit and Its Ligand, Stem Cell Factor, in Mast Cell Apoptosis. <i>International Archives of Allergy and Immunology</i> , 1995, 107, 136-138.	2.1	43
95	A Truncated Splice-Variant of the Fc μ RI β 2 Receptor Subunit Is Critical for Microtubule Formation and Degranulation in Mast Cells. <i>Immunity</i> , 2013, 38, 906-917.	14.3	43
96	Analysis of the lineage relationship between mast cells and basophils using the c-kit D816V mutation as a biologic signature. <i>Journal of Allergy and Clinical Immunology</i> , 2005, 115, 1155-1161.	2.9	42
97	Activity of imatinib in systemic mastocytosis with chronic basophilic leukemia and a PRKG2-PDGFRB fusion. <i>Haematologica</i> , 2008, 93, 49-56.	3.5	42
98	Amplification mechanisms for the enhancement of antigen-mediated mast cell activation. <i>Immunologic Research</i> , 2009, 43, 15-24.	2.9	42
99	Mast cell ontogeny and apoptosis. <i>Experimental Dermatology</i> , 1995, 4, 227-230.	2.9	41
100	High-resolution tracking of cell division demonstrates differential effects of TH1 and TH2 cytokines on SCF-dependent human mast cell production in vitro: correlation with apoptosis and Kit expression. <i>Blood</i> , 2005, 105, 592-599.	1.4	41
101	Concurrent Inhibition of Kit- and Fc μ RI-Mediated Signaling: Coordinated Suppression of Mast Cell Activation. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2008, 324, 128-138.	2.5	40
102	Mastocytosis associated with a rare germline KIT K509I mutation displays a well-differentiated mast cell phenotype. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 134, 178-187.e1.	2.9	38
103	Mastocytosis-derived extracellular vesicles deliver miR-23a and miR-30a into pre-osteoblasts and prevent osteoblastogenesis and bone formation. <i>Nature Communications</i> , 2021, 12, 2527.	12.8	38
104	Defining baseline variability of serum tryptase levels improves accuracy in identifying anaphylaxis. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 1010-1017.e10.	2.9	38
105	Targeting Kit Activation: A Potential Therapeutic Approach in the Treatment of Allergic Inflammation. <i>Inflammation and Allergy: Drug Targets</i> , 2007, 6, 57-62.	1.8	36
106	Regression of Urticaria Pigmentosa in Adult Patients With Systemic Mastocytosis. <i>Archives of Dermatology</i> , 2002, 138, 785-90.	1.4	35
107	Mast cells, which interact with <i>Escherichia coli</i> , up-regulate genes associated with innate immunity and become less responsive to Fc μ RI-mediated activation. <i>Journal of Leukocyte Biology</i> , 2006, 79, 339-350.	3.3	35
108	Personalized Management Strategies in Mast Cell Disorders: ECNM-AIM User's Guide for Daily Clinical Practice. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 1999-2012.e6.	3.8	35

#	ARTICLE	IF	CITATIONS
109	Detection of <i>KIT</i> D816V in peripheral blood of children with manifestations of cutaneous mastocytosis suggests systemic disease. <i>British Journal of Haematology</i> , 2018, 183, 775-782.	2.5	34
110	Mastocytosis-derived extracellular vesicles exhibit a mast cell signature, transfer KIT to stellate cells, and promote their activation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E10692-E10701.	7.1	34
111	Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 3918-3928.	3.8	33
112	Emerging mechanisms contributing to mast cell-mediated pathophysiology with therapeutic implications. , 2021, 220, 107718.		32
113	Radiotherapy of Refractory Bone Pain Due to Systemic Mast Cell Disease. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1994, 17, 328-330.	1.3	31
114	Distinct transcriptome profiles differentiate nonsteroidal anti-inflammatory drug-dependent from nonsteroidal anti-inflammatory drug-independent food-induced anaphylaxis. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 137-146.	2.9	31
115	COVID-19 Vaccination in Mastocytosis: Recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM). <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 2139-2144.	3.8	31
116	Clinical relevance of inherited genetic differences in human tryptases. <i>Annals of Allergy, Asthma and Immunology</i> , 2021, 127, 638-647.	1.0	30
117	An optimized protocol for the generation and functional analysis of human mast cells from CD34 + enriched cell populations. <i>Journal of Immunological Methods</i> , 2017, 448, 105-111.	1.4	28
118	Oncogenic D816V-KIT signaling in mast cells causes persistent IL-6 production. <i>Haematologica</i> , 2020, 105, 124-135.	3.5	26
119	A randomized double-blind, placebo-controlled study of omalizumab for idiopathic anaphylaxis. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 1004-1010.e2.	2.9	25
120	Genetically modified crops and allergenicity. <i>Nature Immunology</i> , 2005, 6, 857-860.	14.5	24
121	IgE-FcγRI Interactions Determine HIV Coreceptor Usage and Susceptibility to Infection during Ontogeny of Mast Cells. <i>Journal of Immunology</i> , 2009, 182, 6401-6409.	0.8	24
122	Demonstration and characterization of a transient arthritis in rats following sensitization of synovial mast cells with antigen-specific ige and parenteral challenge with specific antigen. <i>Arthritis and Rheumatism</i> , 1988, 31, 1063-1067.	6.7	23
123	Interferon-γ enhances both the anti-bacterial and the pro-inflammatory response of human mast cells to <i>Staphylococcus aureus</i> . <i>Immunology</i> , 2015, 146, 470-485.	4.4	23
124	Description and Characterization of a Novel Human Mast Cell Line for Scientific Study. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5520.	4.1	23
125	Risk and management of patients with mastocytosis and MCAS in the SARS-CoV-2 (COVID-19) pandemic: Expert opinions. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 300-306.	2.9	23
126	Critical Signaling Events in the Mechanoactivation of Human Mast Cells through p.C492Y-ADGRE2. <i>Journal of Investigative Dermatology</i> , 2020, 140, 2210-2220.e5.	0.7	23

#	ARTICLE	IF	CITATIONS
127	Cytogenetic abnormalities and their lack of relationship to the Asp816Val c-kit mutation in the pathogenesis of mastocytosis. <i>Journal of Allergy and Clinical Immunology</i> , 1998, 102, 523-524.	2.9	21
128	Thrombopoietin alone or in the presence of stem cell factor supports the growth of KIT(CD117)low/MPL(CD110)+ human mast cells from hematopoietic progenitor cells. <i>Experimental Hematology</i> , 2005, 33, 413-421.	0.4	21
129	Glycogen Synthase Kinase 3 β Activation Is a Prerequisite Signal for Cytokine Production and Chemotaxis in Human Mast Cells. <i>Journal of Immunology</i> , 2010, 184, 564-572.	0.8	21
130	Clinical Impact of Inherited and Acquired Genetic Variants in Mastocytosis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 411.	4.1	21
131	Secretion of Interleukin-1 Receptor Antagonist from Human Mast Cells after Immunoglobulin E-Mediated Activation and after Segmental Antigen Challenge. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2001, 25, 685-691.	2.9	20
132	Mast Cell Migratory Response to Interleukin-8 Is Mediated Through Interaction With Chemokine Receptor CXCR2/Interleukin-8RB. <i>Blood</i> , 1999, 93, 2791-2797.	1.4	20
133	Standards of Genetic Testing in the Diagnosis and Prognostication of Systemic Mastocytosis in 2022: Recommendations of the EU-US Cooperative Group. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 1953-1963.	3.8	20
134	Twelve-year follow-up of omalizumab therapy for anaphylaxis in 2 patients with systemic mastocytosis. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 1314-1316.	3.8	19
135	Clinical impact and proposed application of molecular markers, genetic variants, and cytogenetic analysis in mast cell neoplasms: Status 2022. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 1855-1865.	2.9	19
136	Preclinical human models and emerging therapeutics for advanced systemic mastocytosis. <i>Haematologica</i> , 2018, 103, 1760-1771.	3.5	18
137	Drug-induced mast cell eradication: A novel approach to treat mast cell activation disorders?. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 1866-1874.	2.9	18
138	KIT GNNK splice variants: Expression in systemic mastocytosis and influence on the activating potential of the D816V mutation in mast cells. <i>Experimental Hematology</i> , 2013, 41, 870-881.e2.	0.4	17
139	Incorporating Tryptase Genotyping Into the Workup and Diagnosis of Mast Cell Diseases and Reactions. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 1964-1973.	3.8	17
140	Expression of MRGPRX2 in skin mast cells of patients with maculopapular cutaneous mastocytosis. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 3841-3843.e1.	3.8	16
141	Regulation of normal and neoplastic human mast cell development in mastocytosis. <i>Transactions of the American Clinical and Climatological Association</i> , 2005, 116, 185-203; discussion 203-4.	0.5	15
142	Targeting Mast Cells with Biologics. <i>Immunology and Allergy Clinics of North America</i> , 2020, 40, 667-685.	1.9	14
143	Growth of Human Mast Cells from Bone Marrow and Peripheral Blood-Derived CD34+ Pluripotent Hematopoietic Cells. <i>Methods in Molecular Biology</i> , 2015, 1220, 155-162.	0.9	14
144	Glycogen Synthase Kinase-3 β Is a Prosurvival Signal for the Maintenance of Human Mast Cell Homeostasis. <i>Journal of Immunology</i> , 2011, 187, 5587-5595.	0.8	13

#	ARTICLE	IF	CITATIONS
145	S1P4 Regulates Passive Systemic Anaphylaxis in Mice but Is Dispensable for Canonical IgE-Mediated Responses in Mast Cells. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1279.	4.1	12
146	Impulse oscillometry identifies peripheral airway dysfunction in children with adenosine deaminase deficiency. <i>Orphanet Journal of Rare Diseases</i> , 2015, 10, 159.	2.7	10
147	Regulation of Reactive Oxygen Species and the Antioxidant Protein DJ-1 in Mastocytosis. <i>PLoS ONE</i> , 2016, 11, e0162831.	2.5	9
148	Chromogranin A is not a biomarker of mastocytosis. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 687-689.e4.	3.8	8
149	Targeting Sphingosine Kinase Isoforms Effectively Reduces Growth and Survival of Neoplastic Mast Cells With D816V-KIT. <i>Frontiers in Immunology</i> , 2018, 9, 631.	4.8	8
150	Seafood toxins. <i>Clinical Reviews in Allergy</i> , 1993, 11, 241-60.	1.0	8
151	Interaction of DJ-1 with Lyn is essential for IgE-mediated stimulation of human mast cells. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 195-206.e8.	2.9	7
152	Assessment of Osteoporosis and Fracture Risk in Mastocytosis within a North American Cohort. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 4459-4467.e10.	3.8	6
153	A personal perspective on mentoring. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 548-549.	2.9	5
154	Skewed Lymphocyte Subpopulations and Associated Phenotypes in Patients with Mastocytosis. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 292-301.e2.	3.8	5
155	Inhibition of Allergic Reactivity through Targeting Fc ϵ RI-Bound IgE with Humanized Low-Affinity Antibodies. <i>Journal of Immunology</i> , 2019, 203, 2777-2790.	0.8	4
156	Elevation in histamine and tryptase following exercise in patients with mastocytosis. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 1310-1313.e2.	3.8	3
157	Aldh2 Attenuates Stem Cell Factor/Kit-Dependent Signaling and Activation in Mast Cells. <i>International Journal of Molecular Sciences</i> , 2019, 20, 6216.	4.1	3
158	Mast cells, basophils, and mastocytosis. , 2013, , 284-297.		3
159	Decoding the intricacies of the mast cell compartment. <i>British Journal of Haematology</i> , 2021, , .	2.5	2
160	Acute increases in total serum tryptase unassociated with hemodynamic instability in diffuse cutaneous mastocytosis. <i>Annals of Allergy, Asthma and Immunology</i> , 2022, 129, 249-252.	1.0	2
161	Providing the TORC for cell cycle progression in neoplastic mast cells. <i>Cell Cycle</i> , 2012, 11, 210-211.	2.6	1
162	Maculopapular Cutaneous Mastocytosis in a Diverse Population. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 2845-2847.	3.8	1

#	ARTICLE	IF	CITATIONS
163	Reply. Journal of Allergy and Clinical Immunology, 2019, 143, 451-452.	2.9	1
164	A study of microbial translocation markers in mastocytosis. Clinical and Experimental Allergy, 2021, 51, 369-372.	2.9	1
165	Demonstration and implications of IL-3 upregulation of CD25 expression on human mast cells. Journal of Allergy and Clinical Immunology, 2021, , .	2.9	1
166	Systemic mastocytosis. , 2012, , 369-378.		0
167	Mast Cell Precursors and Signaling Pathways. , 2010, , 283-295.		0
168	History and Current Status of Mastocytosis Research in the European Competence Network on Mastocytosis. , 2020, , 287-299.		0
169	Remission of indolent systemic mastocytosis in the absence of targeted therapy. Journal of Allergy and Clinical Immunology: in Practice, 2022, , .	3.8	0